Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Plazomicin (Zemdri) is indicated for the treatment of patients 18 years or older with complicated urinary tract infections (cUTI), including pyelonephritis.
• The information was derived from a single study, which was a randomized controlled trial comparing plazomicin to meropenem in treating cUTIs.
• In terms of effectiveness, at day 5, clinical cure and microbiologic eradication were slightly lower in the plazomicin group compared to the meropenem group. However, by the test-of-cure visit time point, plazomicin showed superior results in composite cure rates and higher microbiologic eradication rates among resistant Enterobacteriaceae.
• There is an increased risk of nephrotoxicity with Zemdri as demonstrated by elevated serum creatinine levels compared to those treated with meropenem.
• While specific subgroup data are not detailed within this study beyond adults aged 18 years or older suffering from cUTIs caused by multidrug-resistant Enterobacteriaceae; it suggests that Zemdri may be suitable for these individuals.
• Despite its potential nephrotoxicity risks, Plazomicin represents a valuable option particularly where multidrug-resistant pathogens are involved but requires careful consideration depending on individual patient risk factors and susceptibilities.